Laboratory Corporation of America Holdings (LH)

Return on equity (ROE)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (ttm) US$ in thousands 418,000 661,200 830,700 1,000,400 1,279,100 1,756,000 1,990,500 2,099,300 2,377,300 2,762,600 2,878,700 2,642,900 1,556,100 844,900 -175,700 -216,900 285,900 216,700 852,700 896,100
Total stockholders’ equity US$ in thousands 7,875,000 7,873,100 8,785,000 10,341,500 10,096,600 10,092,200 10,400,700 10,721,100 10,273,400 10,601,400 10,322,000 10,098,400 9,436,600 8,239,100 7,352,700 7,020,100 7,643,900 7,020,100 7,144,400 7,111,300
ROE 5.31% 8.40% 9.46% 9.67% 12.67% 17.40% 19.14% 19.58% 23.14% 26.06% 27.89% 26.17% 16.49% 10.25% -2.39% -3.09% 3.74% 3.09% 11.94% 12.60%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $418,000K ÷ $7,875,000K
= 5.31%

The return on equity (ROE) of Laboratory Corp. Of America Holdings has exhibited a declining trend over the last eight quarters. The ROE figures have decreased from 19.58% in Q1 2022 to 5.31% in Q4 2023. This indicates a significant decrease in the company's ability to generate profits from its shareholders' equity during this period.

The decreasing trend in ROE suggests that the company's profitability relative to its equity has been weakening over time. This could be a cause for concern as lower ROE may indicate inefficiencies in the utilization of equity capital or declining profitability of the company.

It is important for investors and stakeholders to closely monitor this trend to understand the underlying factors impacting the company's return on equity and assess whether management strategies are effective in improving and optimizing the company's financial performance.


Peer comparison

Dec 31, 2023

Company name
Symbol
ROE
Laboratory Corporation of America Holdings
LH
5.31%
Fulgent Genetics Inc
FLGT
-14.77%
Quest Diagnostics Incorporated
DGX
13.54%
RadNet Inc
RDNT
0.48%